MY185481A - Osteoclast inhibitors for pain - Google Patents
Osteoclast inhibitors for painInfo
- Publication number
- MY185481A MY185481A MYPI2016704377A MYPI2016704377A MY185481A MY 185481 A MY185481 A MY 185481A MY PI2016704377 A MYPI2016704377 A MY PI2016704377A MY PI2016704377 A MYPI2016704377 A MY PI2016704377A MY 185481 A MY185481 A MY 185481A
- Authority
- MY
- Malaysia
- Prior art keywords
- pain
- osteoclast inhibitors
- osteoclast
- inhibitors
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (28)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201414228241A | 2014-05-27 | 2014-05-27 | |
US14/288,716 US8835650B1 (en) | 2014-01-30 | 2014-05-28 | Substituted imidazolium compounds for treating disease |
US14/288,720 US8865757B1 (en) | 2014-05-28 | 2014-05-28 | Therapeutic compositions comprising imidazole and imidazolium compounds |
US14/288,713 US8901162B1 (en) | 2014-01-30 | 2014-05-28 | Substituted imidazolium compounds for treating disease |
US201462012112P | 2014-06-13 | 2014-06-13 | |
US14/310,811 US8822436B1 (en) | 2012-05-14 | 2014-06-20 | Compositions for oral administration of zoledronic acid or related compounds for treating disease |
US14/336,642 US20140329773A1 (en) | 2012-05-14 | 2014-07-21 | Compositions for Oral Administration of Zoledronic Acid or Related Compounds for Treating Disease |
US14/446,184 US9006279B1 (en) | 2014-01-30 | 2014-07-29 | Substituted imidazolium compounds for treating disease |
PCT/US2014/050427 WO2015060924A1 (fr) | 2013-10-25 | 2014-08-08 | Compositions pour administration orale d'acide zolédronique ou de composés associés pour le traitement de maladies |
US14/457,659 US20140349974A1 (en) | 2014-08-12 | 2014-08-12 | Zoledronic acid dosage forms for the treatment of pain |
US14/481,097 US8962599B1 (en) | 2014-05-27 | 2014-09-09 | Therapeutic compositions comprising imidazole and imidazolium compounds |
US201462053619P | 2014-09-22 | 2014-09-22 | |
US14/495,732 US9127069B1 (en) | 2014-06-11 | 2014-09-24 | Compositions comprising rank/rankl antagonists and related compounds for treating pain |
US14/530,556 US20150051175A1 (en) | 2012-05-14 | 2014-10-31 | Co-Administration of Steroids and Zoledronic Acid to Prevent and Treat Pain |
US14/536,526 US20150057250A1 (en) | 2012-05-14 | 2014-11-07 | Inhibitors of osteoclast activity for treating arthritis |
US14/538,709 US9290575B2 (en) | 2014-06-11 | 2014-11-11 | Compositions comprising RANK/RANKL antagonists and related compounds for treating pain |
US14/540,333 US9216168B1 (en) | 2014-05-27 | 2014-11-13 | Therapeutic compositions comprising imidazole and imidazolium compounds |
US14/604,524 US9211257B2 (en) | 2012-05-14 | 2015-01-23 | Osteoclast inhibitors for knee conditions |
US14/605,822 US9216153B2 (en) | 2012-05-14 | 2015-01-26 | Osteoclast inhibitors for knee conditions |
US14/607,947 US9289384B2 (en) | 2012-05-14 | 2015-01-28 | Osteoclast inhibitors for knee conditions |
US14/607,985 US9289385B2 (en) | 2012-05-14 | 2015-01-28 | Osteoclast inhibitors for knee conditions |
US14/608,855 US9079927B1 (en) | 2014-05-27 | 2015-01-29 | Substituted imidazolium compounds for treating disease |
US14/625,457 US9427403B2 (en) | 2012-05-14 | 2015-02-18 | Methods for the safe administration of imidazole or imidazolium compounds |
US201562127214P | 2015-03-02 | 2015-03-02 | |
US14/635,857 US9283239B2 (en) | 2012-05-14 | 2015-03-02 | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US14/639,013 US9289441B2 (en) | 2014-08-08 | 2015-03-04 | Osteoclast inhibitors such as zoledronic acid for low back pain treatment |
US14/686,551 US9408860B2 (en) | 2012-05-14 | 2015-04-14 | Compositions for oral administration of zoledronic acid or related compounds for treating low back pain |
PCT/US2015/032739 WO2015184003A1 (fr) | 2014-05-27 | 2015-05-27 | Inhibiteurs d'ostéoclastes contre la douleur |
Publications (1)
Publication Number | Publication Date |
---|---|
MY185481A true MY185481A (en) | 2021-05-19 |
Family
ID=57483086
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MYPI2016704377A MY185481A (en) | 2014-05-27 | 2015-05-27 | Osteoclast inhibitors for pain |
Country Status (3)
Country | Link |
---|---|
AU (3) | AU2017213506B2 (fr) |
CA (3) | CA3194798A1 (fr) |
MY (1) | MY185481A (fr) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130303485A1 (en) * | 2012-05-14 | 2013-11-14 | Herriot Tabuteau | Compositions for Oral Administration of Zoledronic Acid or Related Compounds for Treating Disease |
-
2015
- 2015-05-27 MY MYPI2016704377A patent/MY185481A/en unknown
- 2015-05-27 CA CA3194798A patent/CA3194798A1/fr active Pending
- 2015-05-27 CA CA3114271A patent/CA3114271C/fr active Active
- 2015-05-27 CA CA2950443A patent/CA2950443A1/fr not_active Abandoned
-
2017
- 2017-08-10 AU AU2017213506A patent/AU2017213506B2/en active Active
- 2017-12-06 AU AU2017272199A patent/AU2017272199B2/en active Active
-
2019
- 2019-06-27 AU AU2019204559A patent/AU2019204559B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
AU2017272199A1 (en) | 2017-12-21 |
AU2019204559B2 (en) | 2020-04-16 |
AU2019204559A1 (en) | 2019-07-18 |
CA3114271A1 (fr) | 2015-12-03 |
CA3194798A1 (fr) | 2015-12-03 |
AU2017272199B2 (en) | 2019-03-28 |
CA2950443A1 (fr) | 2015-12-03 |
AU2017213506B2 (en) | 2017-09-07 |
AU2017213506A1 (en) | 2017-08-31 |
CA3114271C (fr) | 2023-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB2541571A (en) | Pharmaceutical compositions | |
MX2018006578A (es) | Formulaciones farmaceuticas topicas para tratar afecciones inflamatorias. | |
EA201591509A1 (ru) | Ингибиторы cdc7 | |
MX2017003516A (es) | Derivados de pirazol como estimuladores de guanilato ciclasa soluble (sgc). | |
NZ724691A (en) | Quinoline derivatives as smo inhibitors | |
EA201791133A1 (ru) | Ингибиторы erk | |
WO2014165090A8 (fr) | Composés pour le traitement de la tuberculose | |
SG10201808940WA (en) | Nox inhibitor and nfкb inhibitor containing methoxyflavone | |
MX2018006632A (es) | Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4). | |
MX2018006700A (es) | Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4). | |
MX2017000306A (es) | Metodos para tratar hipotension. | |
EP3226972A4 (fr) | Méthodes et compositions pour le traitement de la migraine et d'états pathologiques associés à la douleur | |
MX2017016114A (es) | Metodos para tratar o prevenir una proteopatia. | |
NZ722600A (en) | Methods of treating mild brain injury | |
HK1244211A1 (zh) | 治療、預防或降低皮膚感染風險的方法 | |
ZA201703467B (en) | Methods of treating ocular conditions | |
MX2020009966A (es) | Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina. | |
MX2016009655A (es) | Metodos novedosos para el tratamiento del cancer. | |
MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
MX2021006326A (es) | Inhibidores de pcna. | |
JO3541B1 (ar) | علاجات طبية قائمة على اناموريلين | |
PH12017500910A1 (en) | Use of sigma receptor ligands in osteoarthritis | |
MX2021008225A (es) | Composiciones y metodos para tratamiento de crecimiento celular anormal. | |
EP3193610A4 (fr) | Inhibiteurs sélectifs de nav1.7 pour le traitement du diabète | |
MX2017007318A (es) | Metodos de prevencion, reduccion o tratamiento de degeneracion macular. |